Targeted delivery of antibiotics using liposomes and nanoparticles: Research and applications

International Journal of Antimicrobial Agents

Volumn 13, Issue 3, 2000, Pages 155-168

  Pinto Alphandary, Huguette ^a   Andremont, Antoine ^a,b   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Antibiotic; Carrier; Intracellular infection; Liposome; Nanoparticle; Targeting

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CIPROFLOXACIN; CLARITHROMYCIN; DIHYDROSTREPTOMYCIN; DRUG CARRIER; ETHAMBUTOL; FLUCLOXACILLIN; GENTAMICIN; KANAMYCIN; LIPOSOME; NANOPARTICLE; NETILMICIN; OFLOXACIN; PEFLOXACIN; PIPERACILLIN; POLYMER; SISOMICIN; SPARFLOXACIN; STREPTOMYCIN; TOBRAMYCIN; TUBERCULOSTATIC AGENT; VACCINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; ENCAPSULATION; EXPERIMENTAL INFECTION; HUMAN; HUMAN CELL; LIPID COMPOSITION; MOUSE; NONHUMAN; OPSONIZATION; PHAGOSOME; PRIORITY JOURNAL; RAT; REVIEW; SALMONELLA TYPHIMURIUM;

EID: 0033991346     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00121-1     Document Type: Article

References (140)

1. Erlich P. Collected studies in immunity. 1906;442 Wiley, New York.
2. Poste G. Liposomes targeting in vivo: Problems and oppportunities. Biol Cell. 47:1983;19-39.
3. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere A., Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm. 15:1983;335-345.
4. Alving C.R. Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents. Adv Drug Deliv Rev. 2:1988;107-128.
5. Nacucchio M.C., Di Rocco P.H., Sordelli D.O. Liposomes as carriers for antibiotics. Targeted Diagn Ther. 3:1990;337-354.
6. Couvreur P., Fattal E., Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res. 8:1991;1079-1086.
7. Kreuter J. Liposomes and nanoparticles as vehicles for antibiotics. Infection. 19(Suppl 4):1991;S224-S228.
8. Karlowsky J.A., Zhanel G.G. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis. 15:1992;654-667.
9. Bakker-Woudenberg I.A.J.M., Storm G., Woodle M.C. Liposomes in the treatment of infections. J Drug Target. 2:1994;363-371.
10. Bakker-Woudenberg I.A.J.M. Liposomes in the treatment of parasitic, viral, fungal and bacterial infections. J Liposome Res. 5:1995;169-191.
11. Bergers J.J., ten Hagen T.L.M., van Etten E.W.M., Bakker-Woudenberg I.A.J.M. Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm World Sci. 17:1995;1-11.
12. Kreuter J. Nanoparticles - preparation and applications. Donbrow M. Micro-encapsulation in Medicine and Pharmacy. 1992;CRC Press, Boca Raton, FL.
13. Couvreur P., Fattal E., Alphandary H., Puisieux F., Andremont A. Intracellular targeting of antibiotics by means of biodegradable nanoparticles. J Control Release. 19:1992;259-268.
14. Allémann E., Gurny R., Doelker E. Drug-loaded nanoparticles-Preparation methods and drug targeting issues. Eur J Pharm Biopharm. 39:1993;173-191.
15. Couvreur P., Dubernet C., Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur J Pharm Biopharm. 41:1995;2-13.
16. Heym B., Cole S.T. Multidrug resistance in Mycobacterium tuberculosis. Int J Antimicrob Agents. 8:1997;61-70.
17. De Vita V.T. Jr., Broder S., Fauci A.S., Kovacs J.A., Chabner B.A. Developmental therapeutics and the acquired immunodeficiency syndrome. Ann Int Med. 106:1987;568-581.
18. Fischl MA et al. and the AIDS Clinical Trials Group. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Int Med 1990;112:727-737.
19. Salmon D., Detruchis P., Leport C., Bouvet E., Karam D., Meyohas M.C., Coulaud J.P., Vildé J.L. Efficacy of zidovudine in preventing relapses of Salmonella bacteremia in AIDS. J Inf Dis. 163:1991;415-416.
20. Keith B.R., White G., Wilson H.R. In vivo efficacy of zidovudine (3′-azido-3′-deoxythymidine) in experimental gram-negative bacterial infections. Antimicrob Agents Chemother. 33:1989;479-483.
21. van den Broek P.J. Antimicrobial drugs, microorganisms and phagocytes. Rev Infect Dis. 11:1989;213-245.
22. Tulkens P.M. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis. 10:1991;100-106.
23. Barza M. Tissue-directed antibiotic therapy: antibiotic dynamics in cells and tissue. Challenges to antibiotic activity in tissue. Clin Infect Dis. 19:1994;910-915.
24. Silverstein S.C., Kabbash C. Penetration, retention, intracellular localization, and antimicrobial activity of antibiotics within phagocytes. Curr Opin Hematol. 1:1994;85-91.
25. Kaprelyants A.S., Gottschal J.C., Kell D.B. Dormancy in non-sporulating bacteria. FEMS Microbiol Reviews. 104:1993;271-286.
26. Gilbert P., Collier P.J., Brown M.R.W. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy and stringent response. Antimicrob Agents Chemother. 34:1990;1865-1868.
27. Costerton J.W., Cheng K.J., Geesey G.G., Ladd T.I., Nickel J.C., Dasgupta M., Marrie T.J. Bacterial biofilm in nature and disease. Annu Rev Microbiol. 41:1987;435-464.
28. Costerton J.W., Lewandowski Z., Caldwell D.E., Korber D.R., Lappin-Scott H.M. Microbial biofilms. Annu Rev Microbiol. 49:1995;711-745.
29. Eng R.H.K., Hsieh A., Smith S.M. Antibiotic killing of bacteria: comparison of bacteria on surfaces and in liquid, growing and non-growing. Chemotherapy. 41:1995;113-120.
30. Zeiler H.J., Voigt W.H. Efficacy of ciprofloxacin in stationary-phase bacteria in vivo. Am J Med. 82:1987;87-90.
31. Chapman D. Physicochemical properties of phospholipids and lipid-water systems. Gregoriadis G. Liposome technology. 1984;1-18 CRC Press, Boca Raton, FL.
32. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 13:1965;238-252.
33. Sessa G., Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res. 9:1968;310-318.
34. Bangham A.D. Surrogate cells or Trojan horses. The discovery of liposomes. BioEssays. 17:1995;1081-1088.
35. Gregoriadis G. The carrier potential of liposomes in biology and medicine. New England J Med. 295:1976;765-770.
36. Gregoradis G. Liposome preparation and related techniques. Gregoriadis G. Liposome Technology. 1:1993;1-63 CRC Press, Boca Raton, FL.
37. Vemuri S., Rhodes C.T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helvetiae. 70:1995;95-111.
38. Watve R.M., Bellare J.R. Manufacture of liposomes: a review. Current Sci. 68:1995;715-724.
39. Dijkstra J., van Galen W.J.M., Regts J., Scherphof G.L. Uptake and processing of liposomal phospholipids by Kuppfer cells in vitro. Eur J Biochem. 148:1985;391-397.
40. Crowe J.H., Crowe L.M. Factors affecting the stability of drug liposomes. Biochim Biophys Acta. 939:1988;327-334.
41. Fattal E., Rojas J., Youssef M., Couvreur P., Andremont A. Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrob Agents Chemother. 35:1991;770-772.
42. Desiderio J.V., Campbell S.G. Liposome-encapsulated cephalothin in the treatment of experimental murine salmonellosis. J Reticuloendothel Soc. 34:1983;279-287.
43. Bakker-Woundenberg I.A.J.M., Lokerse A.F., Vink Van Den Berg J.C., Roedink F.H., Michel M.F. Free versus liposome-entrapped ampicillin in treatment of Listeria monocytogenes in normal and athymic (nude) mice. J Inf Dis. 151:1985;917-924.
44. Chowdhury M.K.R., Goswami R., Chakrabarti P. Liposome-entrapped penicillins and growth inhibition in some penicillin-resistant bacteria. J Appl Bacteriol. 51:1981;223-227.
45. Nacucchio M.C., Gatto-Bellora M.J., Sordelli D.O., D'Aquino M. Enhanced liposome-mediated activity of piperacillin against staphylococci. Antimicrob Agents Chemother. 27:1985;137-139.
46. Tadakuma T., Ikewaki N., Yasuda T., Tsutsumi M., Saito S., Saito K. Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes. Antimicrob Agents Chemother. 28:1985;28-32.
47. Mimoso I.M., Francisco A.P.G., Cruz M.E.M. Liposomal formulation of netilmicin. Int J Pharm. 147:1997;109-117.
48. Fierer J., Hatlen L., Lin J.P., Estrella D., Mihalko P., Yau-Young A. Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice. Antimicrob Agents Chemother. 34:1990;343-348.
49. Swenson C.E., Stewart K.A., Hammett J.L., Fitzsimmons W.E., Ginsberg R.S. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother. 34:1990;235-240.
50. Fountain M.W., Weiss S.K., Fountain A.G., Shen A., Lenk R.P. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides. J Infect Dis. 152:1985;529-535.
51. Hernandez-Caselles T., Vera A., Crespo F., Villalain J., Gomez-Fernandez J.C. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin. Am J Vet Res. 50:1989;1486-1488.
52. Vitas A.I., Diaz R., Gamazo C. Protective effect of liposomal gentamicin against systemic acute murine brucellosis. Chemotherapy. 43:1997;204-210.
53. Juliano R.L., Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Comm. 63:1975;651-658.
54. Orozco L.C., Forero M., Wasserman M., Ahumada J.L. Distribution of liposomes in tuberculous mice. Tubercle. 71:1990;209-214.
55. Majumdar S., Flasher D., Friend D.S., Nassos P., Yajko D., Hadley W.K., Düzgünes N. Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages. Antimicrob Agents Chemother. 36:1992;2808-2815.
56. Cynamon M.H., Swenson C.E., Palmer G.S., Ginsberg R.S. Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex in beige mice. Antimicrob Agents Chemother. 33:1989;1179-1183.
57. Gangadharam P.R.J., Perumal V.K., Podapati N.R., Kesavalu L., Iseman M.D. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental M. avium complex infections in beige mice. Antimicrob Agents Chemother. 32:1988;1400-1403.
58. Tomioka H., Saito H., Sato K., Yoneyama T. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Respir Dis. 144:1991;575-579.
59. Gangadharam P.R.J., Ashtekar D.A., Ghori N., Goldstein J.A., Debs R.J., Düzgünes N. Chemotherapeutic potential of free and liposome-encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J Antimicrob Chemother. 28:1991;425-429.
60. Vladimirsky M.A., Ladigina G.A. Antibacterial activity of liposome-entrapped streptomycin in mice infected with Mycobacterium tuberculosis. Biomedicine. 36:1982;375-377.
61. Swenson C.E., Popescu M.C., Ginsberg R.S. Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol. 15:1988;S1-S31.
62. Leitzke S., Bucke W., Borner K., Müller R., Hahn H., Ehlers S. Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother. 42:1998;459-461.
63. Bermudez L.E.M., Yau-Young A.O., Lin J.P., Cogger J., Young L.S. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides. J Infect Dis. 161:1990;1262-1268.
64. Düzgünes N., Perumal V.K., Kesavalu L., Goldstein J.A., Debs R.J., Gangadharam P.R.J. Enhanced effect of liposome encapsulated amikacin on Mycobacterium avium-Mycobacterium intracellulare complex infection in beige mice. Antimicrob Agents Chemother. 32:1988;1404-1411.
65. Düzgünes N., Ashtekar D.R., Flasher D.L., Gori N., Debs R.J., Friend D.S., Gangadharam P.R.J. Treatment of Mycobacterium avium-M. intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J Infect Dis. 164:1991;143-151.
66. Petersen E.A., Grayson J.B., Hersh E.M., Dorr R.T., Chiang S.M., Oka M., Profitt R.T. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model. J Antimicrob Chemother. 38:1996;819-828.
67. Fielding R.M., Lewis R.O., Moon-Mc Dermott L. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes. Pharm Res. 15:1998;1775-1781.
68. Klemens S.P., Cynamon M.H., Swenson C.E., Ginsberg R.S. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 34:1990;967-970.
69. Nightingale S.D., Saletan S.L., Swenson C.E., Lawrence A.J., Watson D.A., Pilkiewicz F.G., Silverman E.G., Cal S.X. Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrob Agents Chemother. 37:1993;1869-1872.
70. Assil K.K., Frucht-Perry J., Ziegler E., Schanzlin D., Schneiderman T., Weinreb R.N. Tobramycin liposomes. Single subconjunctival therapy of pseudomonal keratitis. Investig Ophtalmo Visual Sc. 32:1991;3216-3220.
71. Di Rocco P.H., Nacucchio M.C., Sordelli D.O., Mancuso F., Hooke A.M. The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection. Infection. 20:1992;360-364.
72. Frucht-Perry J., Assil K.K., Ziegler E., Douglas H., Brown S.I., Schanzlin D., Weinreb R.N. Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratitis. Cornea. 11:1992;393-397.
73. Omri A., Beaulac C., Bouhajib M., Montplaisir S., Sharkawi M., Lagacé J. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 38:1994;1090-1095.
74. Price C.I., Horton J.W., Baxter C.R. Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics. Surgery. 115:1994;480-487.
75. Beaulac C., Clément-Major S., Hawari J., Lagacé J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother. 40:1996;665-669.
76. Beaulac C., Clément-Major S., Hawari J., Lagacé J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J Microencapsulation. 14:1997;335-348.
77. Raz A., Bucana C., Fogler W.E., Poste G., Fidler I.J. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 41:1981;487-494.
78. Magallanes M., Dijkstra J., Fierer J. Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis. Antimicrob Agents Chemother. 37:1993;2293-2297.
79. Wong J.P., Cherwonogrodzky J.W., Di Ninno V.L., De la Cruz R., Saravolac E.G. Liposome-encapsulated ciprofloxacin for the prevention and treatment of infectious diseases caused by intracellular pathogens. Shek P.N. Liposomes in biomedical applications. 1995;105-120 Harwood Academic Publishers, Germany.
80. Herrmann J.L., Lagrange P.H. Intracellular activity of zidovudine (3′-azido-3′-deoxythymidine, AZT) against Salmonella typhimurium in the macrophage cell line J774-2. Antimicrob Agents Chemother. 36:1992;1081-1085.
81. Webb M.S., Boman N.L., Wiseman D.J., Saxon D., Sutton K., Wong K.F., Logan P., Hope M.J. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother. 42:1998;45-52.
82. Moghimi S.M., Davis S.S. Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. Crit Rev Ther Drug Carrier Syst. 11:1994;31-59.
83. Allen T.M. Stealth liposomes: five years on. J Liposome Res. 2:1992;289-305.
84. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim Biophys Acta. 1113:1992;171-199.
85. Bakker-Woudenberg I.A.J.M., Lokerse A.F., Kate M.T., Mouton J.W., Woodle M.C., Storm G. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis. 168:1993;164-171.
86. Storm G., Bakker-Woudenberg I.A.J.M., Schiffelers R.M., Oyen W.J.G., Crommelin D.J.A., Corstens F.H.M., Boerman O.C. Diagnostic and therapeutic targeting of infections and inflammatory diseases using sterically stabilized liposomes. Gregoriadis G., McCormack B. Targeting of drugs 6: Strategies for stealth therapeutic systems. 1998;121-130 Plenum Press, New York.
87. Fielding R.M., Mukwaya G., Sandhaus R.A. Clinical and preclinical studies with low-clearance liposomal amikacin (MiKasomeR). Woodle M.C., Storm G. Long-circulating liposomes: old drugs, new therapeutics. 1998;Chapter 15 Springer Verlag, New York.
88. Sunamoto J., Goto M., Iida T., Hara K., Saito A., Tomonaga A. Unexpected tissue distribution of liposome coated with amylopectin derivatives and successful use in the treatment of experimental legionnaire's disease. Gregoriadis G., Poste G., Senior J., Trouet A. Receptor mediated targeting of drugs. 1983;359-371 Plenum Press, New York.
89. Ito M., Ishida E., Tanabe F., Nori M., Shigeta S. Inhibitory effect of liposome-encapsulated penicillin G on growth of Listeria monocytogenes in mouse macrophages. Tohoku J Exp Med. 150:1986;281-286.
90. Bakker-Woudenberg I.A.J.M., Lokerse A.F., Vink Van Den Berg J.C., Roedink F.H., Michel M.F. Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages. Antimicrob Agents Chemother. 30:1986;295-300.
91. Bakker-Woudenberg I.A.J.M., Lokerse A.F., Roedink F.H. Antibacterial activity of liposome-entrapped ampicillin in vivo and in vitro in relation to the lipid composition. J Pharmacol Exp Ther. 251:1989;321-327.
92. Bakker-Woudenberg I.A.J.M., Lokerse A.F., Roedink F.H. Effect of lipid composition on activity of liposome-entrapped ampicillin against intracellular Listeria monocytogenes. Antimicrob Agents Chemother. 32:1988;1560-1564.
93. Desiderio J.V., Campbell S.G. Intraphagocytic killing of Salmonella typhimurium by liposome-encapsulated cephalothin. J Inf Dis. 148:1983;563-570.
94. Roesler J., Hockertz S., Vogt B., Lohmann-Matthes M.L. Staphylococci surviving intracellularly in phagocytes from patients suffering from chronic granulomatous disease are killed in vitro by antibiotics encapsulated in liposomes. J Clin Invest. 88:1991;1224-1229.
95. Stevenson M., Baillie A.J., Richards R.M.E. Enhanced activity of streptomycin and chloramphenicol against intracellular Escherichia coli in the J774 macrophage cell line mediated by liposome delivery. Antimicrob Agents Chemother. 24:1983;742-749.
96. Dees C., Fountain M.W., Taylor J.R., Schultz R.D. Enhanced intraphagocytic killing of Brucella abortus in bovine mononuclear cells by liposomes containing gentamicin. Vet Immunol Immunopathol. 8:1985;171-182.
97. Dees C., Schultz R.D. The mechanism of enhanced intraphagocytic killing of bacteria by liposomes containing antibiotics. Vet Immunol Immunopathol. 24:1990;135-146.
98. Bermudez L.E.M., Wu M., Young L.S. Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. J Inf Dis. 156:1987;510-513.
99. Kesavalu L., Goldstein J.A., Debs R.J., Düzgunes N., Gangadharam P.R. Differential effects of free and liposome-encapsulated amikacin on the survival of Mycobacterium avium complex in mouse peritoneal macrophages. Tubercle. 71:1990;215-217.
100. Wichert B.V., Gonzalez-Rothi R.J., Straub L.E., Wichert B.M., Schreier H. Amikacin liposomes: preparation, characterization and in vitro activity against Mycobacterium avium-M. intracellulare infection in alveolar macrophages. Int J Pharm. 78:1992;227-235.
101. Bonventre P.F., Gregoriadis G. Killing of intraphagocytic Staphylococcus aureus by dihydrostreptomycin entrapped within liposomes. Antimicrob Agents Chemother. 13:1978;1049-1051.
102. Fountain M.W., Dees C., Schultz R.D. Enhanced intracellular killing of Staphylococcus aureus by canine monocytes treated with liposomes containing amikacin, gentamicin, kanamycin and tobramycin. Curr Microbiol. 6:1981;373-376.
103. Düzgünes N., Flasher D., Reddy M.V., Luna-Herrera J., Gangadharam P.R. Treatment of intracellular Mycobacterium avium complex by free and liposome-encapsulated sparfloxacin. Antimicrob Agents Chemother. 40:1996;2618-2621.
104. Onyeji C.O., Nightingale C.H., Nicolau D.P., Quintiliani R. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages. Antimicrob Agents Chemother. 38:1994;523-527.
105. Oh Y.K., Nix D.E., Straubinger R.M. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother. 39:1995;2104-2111.
106. Onyeji C.O., Nightingale C.H., Marangos M.N. Enhanced killing of methicillin-resistant Staphylococcus aureus in human macrophages by liposome-entrapped vancomycin and teicoplanin. Infection. 22:1994;1-5.
107. Price C.I., Horton J.W., Baxter C.R. Liposome encapsulation: a method for enhancing the effectiveness of local antibiotics. Surgery. 115:1994;480-487.
108. Niesman M.R. The use of liposomes as drug carriers in ophtalmology. Crit Rev Ther Drug Carrier Syst. 9:1992;1-38.
109. Fishman P.H., Peyman G.A., Lesar T. Intravitreal liposome-encapsulated gentamicin in a rabbit model. Invest Ophtalmol Vis Sci. 27:1986;1103-1106.
110. Zeng S., Hu C., Wei H., Lu Y., Zhang Y., Yang J. Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model. Ophtalmology. 100:1993;1640-1644.
111. Peyman G.A., Charles H.C., Liu K.R., Khoobehi B., Niesman M. Intravitreal liposome-encapsulated drugs: a preliminary human report. Int Ophtalmol. 12:1988;175-182.
112. Sanderson N.M., Jones M.N. Encapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidis. J Drug Target. 4:1996;181-189.
113. Conley J., Yang H., Wilson T., Blasetti K., Di Ninno V., Schnell G., Wong J.P. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob Agents Chemother. 41:1997;1288-1292.
114. Kreuter J., Speiser P.P. New adjuvants on a polymethylmethacrylate base. Infect Immunity. 13:1976;204-210.
115. Couvreur P., Kante B., Roland M., Guiot P., Baudhuin P., Speiser P. Polyalkylcyanoacrylate nanocapsules as potential lysosomotropic carriers. Preparation, morphological and sorptive properties. J Pharm Pharmacol. 31:1979;331-332.
116. Couvreur P, Roland M, Speiser P. Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them. US Patent No. 4.329.332, 1982.
117. Couvreur P., Grislain L., Lenaerts V., Brasseur F., Guiot P., Biernacki A. Biodegradable polymeric nanoparticles as drug carrier for antitumor agents. Guiot P., Couvreur P. Polymeric Nanoparticles and Microspheres. 1986;27-93 CRC Press, Boca Raton, FL.
118. Tulkens P.M. The design of antibiotics capable of an intracellular action. Buri P., Guma A. Drug Targeting. 1985;179-194 Elsevier Science Publishers, Amsterdam.
119. Verdun C., Couvreur P., Vranckx H., Lenaerts V., Roland M. Development of a nanoparticulate controlled-release formulation for human use. J Control Release. 3:1986;205-210.
120. Kante B., Couvreur P., Dubois-Crack G., De Meester C., Guiot P., Roland M., Mercier M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles. I: Free nanoparticles. J Pharm Sci. 7:1982;786-790.
121. Al Khouri F.N., Roblot-Treupel L., Fessi H., Devissaguet J.P., Puisieux F. Development of a new process for the manufacture of polyisobutyl-cyanoacrylate nanocapsules. Int J Pharm. 28:1986;125-132.
122. Lenaerts V., Couvreur P., Christiaens-Leyh D., Joiris E., Rolland M., Rollman B., Speiser P. Degradation of polyisobutylcyanoacrylate nanoparticles. Biomaterials. 5:1984;65-68.
123. Guise V., Jaffray P., Delattre J., Puisieux F., Adolphe M., Couvreur P. Comparative cell uptake of propidium iodide associated with liposomes or nanoparticles. Cell Molec Biol. 33:1987;397-405.
124. Henry-Michelland S., Alonso M.J., Andremont A., Maincent P., Sauzières J., Couvreur P. Attachment of antibiotics to nanoparticles: preparation, drug release and antimicrobial activity in vitro. Int J Pharm. 35:1987;121-127.
125. Fattal E., Youssef M., Couvreur P., Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother. 33:1989;1540-1543.
126. Fattal E., Balland O., Alphandary H., Pecquet S., Puisieux F., Couvreur P., Andremont A. Colloidal carriers of antibiotics as an alternative approach for the treatment of intracellular infections. Raoult D. Antimicrobial agents and intracellular pathogens. 1993;63-72 CRC Press, Boca Raton, FL.
127. Youssef M., Fattal E., Alonso M.J., Roblot-Treupel L., Sauzières J., Tancrède C., Omnès A., Couvreur P., Andremont A. Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice. Antimicrob Agents Chemother. 32:1988;1204-1207.
128. Balland O., Pinto-Alphandary H., Pecquet S., Andremont A., Couvreur P. The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. J Antimicrob Chemother. 33:1994;509-522.
129. Pinto-Alphandary H., Balland O., Laurent M., Andremont A., Puisieux F., Couvreur P. Intracellular vizualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Pharm Res. 11:1994;38-46.
130. Balland O., Pinto-Alphandary H., Viron A., Puvion E., Andremont A., Couvreur P. Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H) ampicillin-loaded nanoparticles. J Antimicrob Chemother. 37:1996;105-115.
131. Page-Clisson M.E., Pinto-Alphandary H., Chachaty E., Couvreur P., Andremont A. Drug targeting by polyalkylcyanoacrylate is not efficient against persistent Salmonella. Pharm Res. 15:1998;542-547.
132. Pardon P., Popoff M.Y., Coynault C., Marly J., Miras I. Virulence-associated plasmids of Salmonella serovar Typhimurium in experimental murine infection. Ann Inst Pasteur/Microbiol. 137B:1986;47-60.
133. Forestier F., Gerrier P., Chaumard C., Quero A.M., Couvreur P., Labarre C. Effect of nanoparticle-bound ampicillin on the survival of Listeria monocytogenes in mouse peritoneal macrophages. J Antimicrob Chemother. 30:1992;173-179.
134. Fawaz F., Bonini F., Maugein J., Lagueny A.M. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. Int J Pharm. 168:1998;255-259.
135. Anwar H., Dasgupta M.K., Costerton J.W. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 34:1990;2043-2046.
136. Desnottes J.F. Recherche de nouveaux antibactériens. Evolution des méthodes d'évaluation microbiologique. Bull Soc Fr Microbiol (H.S.). 10:1995;37-44.
137. Sukupolvi S., Edelstein A., Rhen M., Normark S.J., Pfeifer J.D. Development of a murine model of chronic Salmonella infection. Infect Immun. 65:1997;838-842.
138. s. J Bact. 173:1991;4474-4481.
139. Hof H. Therapeutic activities of antibiotics in Listeriosis. Infection. 19(Suppl 4):1991;S229-S233.
140. Bamberger D.M., Fields M.T., Herndon B.L. Efficacies of various antimicrobial agents in treatment of Staphylococcus aureus abscesses and correlation with in vitro tests of antimicrobial activity and neutrophil killing. Antimicrob Agents Chemother. 35:1991;2335-2339.